BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Huang W, Li X, Yi M, Zhu S, Chen W. Targeted delivery of siRNA against hepatitis B virus by preS1 peptide molecular ligand. Hepatol Res. 2014;44:897-906. [PMID: 23799901 DOI: 10.1111/hepr.12189] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
Number Citing Articles
1 Chin W, Ang SK, Chu JJH. Recent advances in therapeutic recruitment of mammalian RNAi and bacterial CRISPR-Cas DNA interference pathways as emerging antiviral strategies. Drug Discovery Today 2017;22:17-30. [DOI: 10.1016/j.drudis.2016.08.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
2 Toita R, Kawano T, Kang JH, Murata M. Applications of human hepatitis B virus preS domain in bio- and nanotechnology. World J Gastroenterol 2015; 21(24): 7400-7411 [PMID: 26139986 DOI: 10.3748/wjg.v21.i24.7400] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
3 Hajiasgharzadeh K, Somi MH, Shanehbandi D, Mokhtarzadeh A, Baradaran B. Small interfering RNA-mediated gene suppression as a therapeutic intervention in hepatocellular carcinoma. J Cell Physiol 2019;234:3263-76. [PMID: 30362510 DOI: 10.1002/jcp.27015] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
4 Ahmed M, Wang F, Levin A, Le C, Eltayebi Y, Houghton M, Tyrrell L, Barakat K. Targeting the Achilles heel of the hepatitis B virus: a review of current treatments against covalently closed circular DNA. Drug Discov Today 2015;20:548-61. [PMID: 25622780 DOI: 10.1016/j.drudis.2015.01.008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
5 Biscaglia F, Quarta S, Villano G, Turato C, Biasiolo A, Litti L, Ruzzene M, Meneghetti M, Pontisso P, Gobbo M. PreS1 peptide-functionalized gold nanostructures with SERRS tags for efficient liver cancer cell targeting. Materials Science and Engineering: C 2019;103:109762. [DOI: 10.1016/j.msec.2019.109762] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
6 Maepa MB, Roelofse I, Ely A, Arbuthnot P. Progress and Prospects of Anti-HBV Gene Therapy Development. Int J Mol Sci 2015;16:17589-610. [PMID: 26263978 DOI: 10.3390/ijms160817589] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
7 Sun H, Chang L, Yan Y, Wang L. Hepatitis B virus pre-S region: Clinical implications and applications. Rev Med Virol 2020. [PMID: 33314434 DOI: 10.1002/rmv.2201] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Gao L, Yang J, Feng J, Liu Z, Dong Y, Luo J, Yu L, Wang J, Fan H, Ma W, Liu T. PreS/2-21-Guided siRNA Nanoparticles Target to Inhibit Hepatitis B Virus Infection and Replication. Front Immunol 2022;13:856463. [DOI: 10.3389/fimmu.2022.856463] [Reference Citation Analysis]
9 Shi X, Zhang X, Chang Y, Jiang B, Deng R, Wang A, Zhang G. Nonstructural protein 11 (nsp11) of porcine reproductive and respiratory syndrome virus (PRRSV) promotes PRRSV infection in MARC-145 cells. BMC Vet Res 2016;12:90. [PMID: 27268206 DOI: 10.1186/s12917-016-0717-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
10 Shukla RS, Qin B, Cheng K. Peptides used in the delivery of small noncoding RNA. Mol Pharm 2014;11:3395-408. [PMID: 25157701 DOI: 10.1021/mp500426r] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 5.6] [Reference Citation Analysis]